ArticleBioinformatics (Oxford, England)2026
MMPCS: multi-view molecular pretraining based on consistency information and specific information.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationThe goal of molecular representation learning is to automate the extraction of molecular features, a critical task in cheminformatics and drug discovery. While pretraining models using multiple views like SMILES, 2D graphs, and 3D conformations have advanced the field, integrating them effectively to produce superior representations remains a challenge.
resultsTo bridge this gap, we propose a novel multi-view molecular pretraining method termed MMPCS, which explicitly factorizes representations into consistency and specific information. Our approach utilizes the Graph Isomorphism Network and the RoBERTa model to encode 2D molecular topological graphs and SMILES sequences, respectively. Each resulting molecular embedding is decomposed into a shared consistency component and a view-specific remainder. An autoencoder then aligns the consistency information across views. The combined consistency and view-specific representations serve as input for downstream tasks, enabling precise and task-aware predictions. When benchmarked against 16 state-of-the-art molecular pretraining methods, MMPCS achieved the highest average performance across both classification and regression tasks for molecular property prediction. It also delivered outstanding results in predicting drug-target binding affinity and cancer drug response, demonstrating its robustness and broad applicability. Additionally, a case study on the SARS-CoV-2 Omicron variant highlights the potential of MMPCS in facilitating drug repurposing efforts. AVAILABILITY AND IMPLEMENTATION: The source code and datasets supporting this study are publicly available at GitHub (https://github.com/xmubiocode/MMPCS) and Zenodo (https://doi.org/10.5281/zenodo.18182748).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.